Drug intelligence / Profile preview

pegylated liposomal doxorubicin + temozolomide

Development stage: Unknown
Lead developer: Cooperative Trials Group for Neuro-Oncology
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A combination chemotherapy regimen consisting of pegylated liposomal doxorubicin (PLD) and temozolomide. Temozolomide is an alkylating agent that works by preventing cancer cells from making DNA, while pegylated liposomal doxorubicin is doxorubicin encapsulated in a pegylated liposome with unique pharmacokinetic properties. This combination has been studied primarily for brain tumors including glioblastoma multiforme, as well as for brain metastases from solid tumors and recurrent ovarian cancer.

Brand names: CaelyxTemodal
Other names: PLD + temozolomide

Targets

TOP2A (DNA topoisomerase II)DNA

Beyond the preview

Go deeper on pegylated liposomal doxorubicin + temozolomide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pegylated liposomal doxorubicin + temozolomide.

Explore the full profile